Blombäck M, Edsmyr F, Kockum C, Paul C
Urol Res. 1978;6(2):95-102. doi: 10.1007/BF00255580.
Two drugs, 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan) and estramustine-17-phosphate (Estracyt) were given to patients with poorly differentiated metastatic carcinoma of the prostate. The effect of the drugs on blood coagulation was investigated. Some parameters showed changes during the treatment: Antithrombin III decreased in the Estracyt treated patients to a level which might imply a thrombogenic effect. Fibrinogen decreased, whereas factor VIII showed no consistent change. Normotest changes appeared to correlate with liver damage whereas antithrombin III showed no change. Increased levels of fibrinogen degradation products and fibrinopeptide A (FPA) were more frequent in the group of deteriorating patients. However, the number of FPA analyses were too small for any definite conclusions regarding possible disseminated intravascular coagulation.
给前列腺低分化转移性癌患者使用了两种药物，即2,6-顺式二苯基六甲基环四硅氧烷（西索比坦）和雌莫司汀-17-磷酸酯（癌腺治）。研究了这些药物对血液凝固的影响。治疗期间一些参数出现了变化：接受癌腺治治疗的患者抗凝血酶III降至可能暗示有血栓形成作用的水平。纤维蛋白原减少，而因子VIII没有一致的变化。正常试验变化似乎与肝损伤相关，而抗凝血酶III没有变化。纤维蛋白原降解产物和纤维蛋白肽A（FPA）水平升高在病情恶化的患者组中更常见。然而，FPA分析的数量太少，无法就可能的弥散性血管内凝血得出任何明确结论。
